OBJECTIVES: In Netherlands, the funding for some high cost drugs and particularly biologics was transferred in 2012 to hospital pharmacy dispensation channel. A European study forecast (2012-2016) shown hospital dispensation as a very effective policy to reduce budget impact of branded biologics and increase savings related to biosimilars. Two biologics (anti-TNFs) are indicated for Inflammatory Bowel Disease (IBD) in EU with different mode of administration:  infliximab (Intravenous) and adalimumab (Subcutaneous). The objective of this study was to compare the dispensation channel of anti-TNFs used in IBD across European (EU) top 5 countries. METHODS:  We analyzed dispensation conditions using IMS data from 2011 and official local official websites, France (Haute Autorité de Santé and Health insurance drugs database), Italy (Agenzia Italiana del Farmaco), Spain (Ministerio de Sanidad Servicios Sociales e Igualdad), Germany (Gemeinsamer Bundesausschuss), United Kingdom (Department of Health). RESULTS: In United Kingdom, Spain, Italy, both infliximab and adalimumab dispensation were restricted to hospital channel. In Germany, both infliximab and adalimumab can either be dispensed through retail and hospital channels. In France, adalimumab was available either in hospital and retail channels under exceptional status, and infliximab was dispensed through hospital channels only. The differences across countries could not be related to products labels as they are all approved under European Medicines Agency (EMA) centralized procedure. CONCLUSIONS: It is unlikely that the gaps observed are only related to differences in health care services organization but rather budget constraint like in United Kingdom, Italy and Spain. In Germany and France, the two leading EU pharmaceuticals markets this is not yet the case. Hospital dispensation channel of biologics and biosimilars is a new way to generate savings mainly through tenders.